Extendicare Inc. ("Extendicare" or the "Company") announced today that its wholly owned home health care subsidiary, ParaMed Inc. ("ParaMed" or the "Purchaser"), has entered into an agreement to ...

FDA approved the Sapien 3 transcatheter aortic valve replacement (TAVR) platform for treatment of severe aortic stenosis ...

Edwards Lifesciences announced the FDA approved its transcatheter aortic valve replacement platform for treatment of severe ...

The agency’s decision for the balloon-expandable Sapien 3 platform is based on groundbreaking results from EARLY TAVR.

Edwards Lifesciences (NYSE: EW) received FDA approval for its Sapien 3 TAVR for severe aortic stenosis (AS) without symptoms.

Compared with usual care, a system of electronic provider notification more often enabled patients diagnosed with severe ...

Aortic stenosis is a serious heart valve condition characterized by narrowing and stiffening of the aortic valve, restricting blood flow from the heart to the body. This forces the heart to work ...

Aortic stenosis is the most common valvular lesion in patients above the age of 65. The etiology, presentation, and management of aortic stenosis differs in the elderly compared to younger ...

Aortic stenosis is a serious heart valve condition characterized by narrowing and stiffening of the aortic valve, restricting blood flow from the heart to the body. This forces the heart to work ...

Subjects with severe aortic stenosis who underwent treatment with either the Evolut TAVR or surgery exhibited “comparable” rates of all-cause death or disabling stroke over five years ...